CureVac

Today our Formulation Platform Director George Dakwar is participating in the Hanson Wade 4th Annual LNP Formulation & Process Development Summit in Boston, as both a conference track chair and presenter.   During the conference, George will share his insights and perspective on new and innovative formulations for novel LNPs and how to translate them for optimized manufacturing and scalability.   At CureVac, we are consistently working to enhance our lipid nanoparticle (LNP) technology platform to achieve greater precision in the delivery of mRNA therapeutics, with the aim to improve targeting and, ultimately, our ability to address disease. You can find more information on the summit here: https://lnkd.in/dkwpvr-j #LNP #LNPDelivery #mRNA #Biotech

Today, we announced the financial results for the fourth quarter and full year 2024 as well as business updates.   Our strategic transformation as a company over the past year has enabled us to explore new areas of disease to address with the power of mRNA. Notably, we are thrilled to have just received clearance from the FDA to initiate a Phase 1 study of our off-the-shelf mRNA-based immunotherapy in squamous non-small cell lung cancer.   On the clinical front, our Phase 1 study of CVGBM in glioblastoma patients continues to progress on track, with enrollment of Part B now complete. Data from this part of the study is expected in the second half of 2025.   For further information on our earnings results and business updates, please find the press release here: https://lnkd.in/edprdX_w #mRNA #Oncology #HealthcareInnovation #Biotech #Immunotherapy

Today we’re recognizing World Health Day! 🌎🩺   April 7th, the World Health Organization’s anniversary, gives us all an opportunity to spread awareness of global health issues as well as how to address them.   As a biotech company, we are fiercely committed to innovating on behalf of patients – across a range of indications – to improve health outcomes, and we strongly believe mRNA holds the power to unlock new ways to drive healthier futures for all.   #WorldHealthDay #HealthForAll #mRNA #Biotech #HealthcareInnovation

It was great to kick off the week at the Leerink Partners Global Healthcare Conference in Miami ☀️ . We always look forward to opportunities to connect with investors and other innovators in biotech – the energy here is fantastic! #mRNA #HealthcareInnovation #Biotech

International Women’s Day marks a special moment to not only celebrate the phenomenal of successes and strengths of women broadly but also recognize the importance of continued progress toward gender equality.   At CureVac, we cherish the diversity of our team and the many talented and remarkable women who contribute in so many different ways to our collective mission to transform patient outcomes. #IWD2025 #InternationalWomensDay

Did you know? The zebra is a key symbol associated with rare conditions and rare disease patients. In medicine, when a patient presents with a medical challenge, common conditions are often explored first. “Zebras” represent the unexpected, the rare.   That’s why today – Rare Disease Day 2025 – be prepared to see some stripes in support of the rare disease community!   We’re sharing stripes in grey, the awareness color for #glioblastoma. GBM is a rare form of cancer the team here is working to address with biotechnology innovation.   #RareDiseaseDay #ShowYourStripes #Biotech #mRNA 

We are thrilled to have been recognized by LexisNexis as a “Top 100 Global Innovator” for 2025 🏆 It is an honor to be part of such prestigious list of companies driving innovation, and – excitingly – it marks the third consecutive year of our inclusion on it.   To determine the list, LexisNexis analyzed companies around the globe based on their respective patent portfolio improvements. At CureVac, we are proud to have created one of the most robust intellectual property portfolios that exists today in mRNA technology.   Please find more information in our press release today announcing this recognition: https://lnkd.in/eVSp7Xyq   #Top100Innovators #InnovationMomentum #mRNA #Biotech

Happy International Day of Women and Girls in Science! Today, we honor the many talented women across the globe who have made contributions to the advancement of science.   This day also gives us an opportunity to acknowledge the importance of promoting science education for girls and ensuring equal opportunity for young women who want to pursue careers in this broad and ever-critical field.   We connected with some of our own esteemed scientists – Janina Gergen, Janine Mühe, and Kristina Kovacikova – who offered some wonderful perspectives as well as great advice for women and girls hoping to break into the sciences.   See what they have to say!   #WomenInScience #STEM #mRNA #Biotech

A diagnosis of cancer is life changing.   World Cancer Day gives us all an opportunity to not only raise awareness of cancer but also recognize the many individuals who have been or are currently impacted by it.   With such a vast disease area, new innovation in medicine is a critical component to securing a healthier and brighter future for patients. In our oncology work at CureVac, we are leveraging mRNA with an aim to one day change health outcomes in glioblastoma.   So today we share the image of a ribbon in grey – the awareness color for brain cancer – in support the many individuals battling this devasting form of disease.   #WorldCancerDay #WorldCancerDay2025 #mRNA #Cancer #HealthcareInnovation #Glioblastoma

We greatly look forward to participating in the 4th Annual mRNA-Based Therapeutics Summit Europe in Frankfurt, Germany this week! And we have quite the lineup there…   Kicking off the conference, our CEO Dr. Alexander Zehnder, MD, MBA, alongside other notable life science leaders, will join a group panel set to discuss the exciting future opportunities in the field of mRNA.   Our CSO Dr. Myriam Mendila will present on current strategies for the development of cancer vaccines as well as share encore data from CureVac’s Phase 1 study of our cancer vaccine candidate (CVGBM) in patients with resected glioblastoma.   And Dr. Ulrike Jaegle, CureVac Vice President of Global Regulatory Affairs & Preclinical Safety, will be on panel exploring the regulatory landscape as it applies to mRNA medicines.   We hope to see you there!   You can find more details on the event here https://ter.li/welq6g   #mRNA #Cancer #Oncology #Glioblastoma #HealthcareInnovation #biotech